Skip to main content
Clinical Trials/NCT06094205
NCT06094205RecruitingNot Applicable

Understanding and Restoring Speech Production Using an Intracortical Brain-computer Interface

Leigh R. Hochberg, MD, PhD.1 site in 1 country2 target enrollmentStarted: October 16, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
2
Locations
1
Primary Endpoint
Sensor implant duration for at least one-year without any device-related Serious Adverse Events or explant

Study Overview

Brief Summary

The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.

Detailed Description

The goal is to develop a new way to help people who lose the ability to speak due to neurological conditions including ALS or stroke, using an implanted medical device called a "brain-computer interface". The implanted medical device measures the person's brain activity as they try to talk and outputs their intended speech. By bypassing the injured parts of the nervous system this way, we can observe how individual brain cells are involved in speaking and working together as a network, to produce speech, and we can learn to decipher this activity to output what the person is trying to say.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Between 18 and 80 years of age
  • •Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders
  • •Complete or incomplete tetraplegia (quadriplegia)
  • •Must live within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment.
  • •(There are additional inclusion criteria)

Exclusion Criteria

  • •Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses
  • •Chronic oral or intravenous steroids or immunosuppressive therapy
  • •Other serious disease or disorder that could seriously affect ability to participate in the study
  • •(There are additional exclusion criteria)

Arms & Interventions

BrainGate Neural Interface System

Experimental

Placement of the BrainGate2 sensor(s) into the speech-related cortex

Intervention: BrainGate Neural Interface System (Device)

Outcomes

Primary Outcomes

Sensor implant duration for at least one-year without any device-related Serious Adverse Events or explant

Time Frame: 1 year

To determine the safety of the Sensor and overall safety of the System. Participants will be considered a success for this safety measure if they are successfully implanted with the Sensor(s) and: 1. the sensors are not explanted for safety reasons during the one-year post-implant evaluation period. 2. there are no device-related Serious Adverse Events that result in death or permanently increased disability during the one-year post-implant evaluation period.

Secondary Outcomes

  • Decoded speech output accuracy(At participant exit from study, or up to 5 years)

Investigators

Sponsor
Leigh R. Hochberg, MD, PhD.
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Leigh R. Hochberg, MD, PhD.

Neurologist

Massachusetts General Hospital

Study Sites (1)

Loading locations...

Similar Trials